Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Oct;25(10):461-6.
doi: 10.1002/clc.4960251005.

Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study

Filippo Crea  1 , Claudia Monaco, Gaetano A Lanza, Elena Maggi, Francesca Ginnetti, Domenico Cianflone, Giampaolo Niccoli, Thomas Cook, Giorgio Bellomo, John Kjekshus
Affiliations
Clinical Trial

Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study

Filippo Crea et al. Clin Cardiol. 2002 Oct.

Abstract

Background and hypothesis: The predictive value of specific markers of infection and autoimmunity for coronary events, such as the effects of statins on inflammation, is still controversial.

Methods: A case-control design was used to compare C-reactive protein (CRP) levels, seropositivity for Chlamydia pneumoniae and Helicobacter pylori, and anti-oxidized low-density lipoprotein (oxLDL) antibody levels in prerandomization blood samples from 129 participants in the Scandinavian Simvastatin Survival Study who died (cases), and from 129 matched participants who were alive during 5-year follow-up (controls).

Results: Patients with CRP levels in the highest quartile had an increased risk of death compared with those in the first through third quartile (odds ratio [OR] = 2.51, 95% confidence interval [CI] 1.3-4.8). Seropositivity for Chlamydia pneumoniae or Helicobacter pylori and anti-oxLDL antibody levels were similar in cases and controls (p = NS). At a 4-month control, simvastatin reduced CRP levels (p = 0.009) while placebo did not (p = NS). However, the risk of death associated with high baseline CRP levels was similar in patients randomized to placebo (OR = 2.36, 95% CI 1.06-5.26) or simvastatin (OR = 3.13, 95% CI 1.06-9.21).

Conclusions: Elevated CRP levels, but not seropositivity for Chlamydia pneumoniae or Helicobacter pylori, nor levels of anti-oxLDL antibodies, predict the risk of death in patients with stable ischemic heart disease. Simvastatin treatment reduces CRP levels, but without affecting the increased risk conferred by higher CRP levels at baseline.

PubMed Disclaimer

References

    1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336 (14): 973–979 - PubMed
    1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Plasma concentration of C‐reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97 (5): 425–428 - PubMed
    1. Kuller LH, Tracy RP, Shaten J, Meilahn EN: Relation of C‐reactive protein and coronary heart disease in the MRFIT nested case‐control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144 (6): 537–547 - PubMed
    1. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH: Relationship of C‐reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17 (6): 1121–1127 - PubMed
    1. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332 (10): 635–641 - PubMed

MeSH terms